Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
NCT03236428Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2017
- Primary completion
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), sponsored by Dana-Farber Cancer Institute. Started Nov 2017; status: active, not recruiting.
02
Drugs
daratumumab
03
Conditions
monoclonal gammopathy of undetermined significance (MGUS)smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT03236428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03236428.